Open AccessCholangiocarcinoma and liver transplantation: What we know so far?
Author(s) -
Ali Reza Safarpour,
Hasan Askari,
Farshid Ejtehadi,
Asaad Azarnezhad,
Ehsan Raeis-Abdollahi,
Amir Tajbakhsh,
Mohammad Foad Abazari,
Firoozeh Tarkesh,
Alireza Shamsaeefar,
Ramin Niknam,
Gholam Reza Sivandzadeh,
Kamran Bagheri Lankarani,
Fardad Ejtehadi
Publication year - 2021
Publication title -
world journal of gastrointestinal pathophysiology
Language(s) - English
Resource type - Journals
ISSN - 2150-5330
DOI - 10.4291/wjgp.v12.i5.84
Subject(s) - medicine , liver transplantation , transplantation , resection , gastroenterology , liver cancer , orthotopic liver transplantation , curative treatment , cancer , general surgery , oncology , surgery , disease
Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.